Enanta Pharmaceuticals Inc (ENTA): Net Income
-$81.89M
Year ended 2025-09-30
-$63.23M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | -$81.89M | n/m | 2025-11-19, From 2024-10-01 |
| 2024-09-30 | -$116.05M | n/m | 2025-11-19, From 2023-10-01 |
| 2023-09-30 | -$133.82M | n/m | 2025-11-19, From 2022-10-01 |
| 2022-09-30 | -$121.75M | n/m | 2024-11-27, From 2021-10-01 |
| 2021-09-30 | -$79.00M | n/m | 2023-11-22, From 2020-10-01 |
| 2020-09-30 | -$36.17M | n/m | 2022-11-23, From 2019-10-01 |
| 2019-09-30 | $46.38M | -35.5% | 2021-11-24, From 2018-10-01 |
| 2018-09-30 | $71.96M | +306.3% | 2020-11-25, From 2017-10-01 |
| 2017-09-30 | $17.71M | -18.3% | 2019-11-27, From 2016-10-01 |
| 2016-09-30 | $21.67M | -72.6% | 2018-11-29, From 2015-10-01 |
| 2015-09-30 | $78.99M | +129.4% | 2017-12-11, From 2014-10-01 |
| 2014-09-30 | $34.44M | +257.7% | 2016-12-09, From 2013-10-01 |
| 2013-09-30 | $9.63M | -55.0% | 2015-12-11, From 2012-10-01 |
| 2012-09-30 | $21.40M | -8.2% | 2014-12-11, From 2011-10-01 |
| 2011-09-30 | $23.31M | n/a | 2013-12-18, From 2010-10-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | -$81.89M | n/m |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $8.57M | n/m |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $6.82M | n/m |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | -$278.67M | n/m |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | -$204.63M | n/m |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | -$101.59M | n/m |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | -$5.31M | n/m |
| Journey Medical Corp (DERM) | 2025-12-31 | -$11.43M | n/m |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | -$342.60M | n/m |
Compare ENTA, SPRO, FBIO, KURA side by side · Screen every company in Pharmaceutical Preparations ↗